Hulton Archive/Getty Images

I’m a neuroscientist who works on memory manipulation. My work helps me recover from addiction

A neuroscientist used his understanding of the brain’s constant change to teach it to crave human connection instead of alcohol.

By Steve Ramirez

What will be born of the marriage of de-extinction firm Colossal and animal cloning biotech Viagen?

Colossal’s purchase of Viagen will help its pursuit of reviving extinct animals — but the ethics and science remain fuzzy.

By Paul Knoepfler

Listeria tied to pasta shows why we need a national foodborne outbreak investigation board

The U.S. needs a nationalfoodborne outbreak investigation board, writes a former FDA official who worked on food safety.

By Frank Yiannas

Robert F. Bukaty/AP

Modern animal models for biomedical research remain far better than alternatives

Biomedical discovery and drug development require greater investment in refining and complementing, not replacing, animal models.

By Anis Barmada

How Congress can still get health care subsidies in place for 2026

Late action after the government reopens could still make a real difference for American families’ wallets and lives, experts writes.

By Emily Gee

The dangerous illusion of ‘peer-to-peer’ review for prior authorization

Insurance company-mandated peer-to-peer prior authorization reviews are opaque and unaccountable, physician writes.

By Alexa B. Kimball

Adobe

Beware the financialization of the global health industry

Complex banking instruments designed to generate money from money using Wall Street and risk logics can’t solve the problem of global health shortfalls.

By S.L. Erikson

Is it ever OK for doctors to ‘fake’ CPR?

On this episode of the “First Opinion Podcast,” guest host Alex Hogan talks to two bioethicists about the controversial “slow code.”

By STAT Staff

A miracle pill for Parkinson’s is 50 years old. Why can’t most of the world get it?

Parkinson's has doubled globally in 25 years but access to a miracle drug is spotty. A STAT First Opinion says this is more than a supply chain problem.

By Michael S. Okun and Ray Dorsey

Adobe

The right place for AI companions in mental health care

A prosthetic relationship with a chatbot isn’t a substitute for intimacy, but a way to approximate it with support, dignity, and hope.

By Harvey Lieberman

STAT+ | The big flaw in Big Pharma’s ‘patient advocacy’

Big Pharma spends millions on patient advocacy — but it often doesn't help patients

By Will Greene